Clinical trials: Tirzepatide
Obesity / Overweight
Effects of Tirzepatide on Gut Microbiota and Gastrointestinal Function After Drug Withdrawal in Obese Patients
This is an observational cohort study. The primary objective is to analyze the dynamic changes in gut microbiota and metabolic profiles in obese patients treated with Tirzepatide.
- Trial name
- NCT07847515
- Testing
- Tirzepatide
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Diabetes Mellitus, Type 2, Obesity
Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy
To assess whether holding incretin-based therapy before endoscopy reduces the likelihood of clinically relevant Residual Gastric Volume (RGV).
- Conditions
- Diabetes Mellitus, Type 2, Obesity, Gastroparesis
- Trial name
- NCT06533527
- Testing
- GLP-1 medication
- Where
- 2 sites in United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Hepatic Insufficiency
A Study of Tirzepatide in Participants With Impaired Liver Function
The purpose of this study is to assess how fast tirzepatide gets into the blood stream and how long it takes the body to remove it in participants with impaired liver function compared to healthy participants.
- Trial name
- NCT03940742
- Testing
- Tirzepatide
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants
The main purpose of this study is to evaluate the body concentration of different forms of bimagrumab, administered alone or with tirzepatide.
- Trial name
- NCT06890611
- Testing
- Bimagrumab, Tirzepatide, Bimagrumab + Tirzepatide Coformulation
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Obesity & Overweight, Cardiometabolic Health Indicators
Tirzepatide Impact Assessment Study
This study examines how two different weight-loss strategies affect heart and metabolic health, as well as changes at the molecular level in the body.
- Conditions
- Obesity & Overweight, Cardiometabolic Health Indicators, Addiction, Eating Disorders
- Trial name
- TIA (NCT07740291)
- Testing
- GLP-1 Receptor Agonist Therapy, Structured Lifestyle Intervention
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Texas Tech University
Obese Adults
Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With Obesity
This study will assess whether a single subcutaneous dose of tirzepatide 7.5 mg , compared with saline placebo, increases total esophageal acid exposure time during a 96-hour wireless pH recording beginning about 48 hours after…
- Trial name
- NCT07893457
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Obesity, Metabolic Disease
Effects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity
The purpose of this study is to conduct a three-arm 52-week, randomized controlled trial with double blind treatment to evaluate the effects of a drug called tirzepatide in combination with an innovative, culturally-appropriate…
- Trial name
- TRZ (NCT06009653)
- Testing
- Standard Care, Culturally-tailored dietary and behavioral intensive lifestyle intervention, Tirzepatide
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Healthy
A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices
The main purpose of this study is to look at the amount of the study drug, tirzepatide, that gets into the blood stream and how long it takes the body to get rid of it when given using two different devices.
- Trial name
- NCT05810597
- Testing
- Tirzepatide, Single Dose Pen, Multi-use Prefilled Pen
- Where
- 3 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Lactation, Weight Loss
Effects of GLP-1 RAs on Human Lactation Outcomes
There is increasing interest in using GLP-1 Receptor Agonist (GLP-1 RA) medications after pregnancy. This study is designed to determine if these medications affect breastmilk production or the nutritional makeup of breastmilk.
- Trial name
- NCT07720414
- Testing
- Injected GLP-1 Receptor Agonists and Dual Agonists
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Healthy Subjects, Obesity
Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes
The phase 1 portion of the study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TLC-6740 after single- and multiple-ascending doses in healthy subjects.
- Conditions
- Healthy Subjects, Obesity, Type 2 Diabetes
- Trial name
- NCT05822544
- Testing
- TLC-6740 Oral Solution, TLC-6740 Tablet, Drug Metabolizing Enzyme
- Where
- 4 sites in New Zealand
- Volunteers
- 564 people, healthy volunteers welcome
- Sponsor
- OrsoBio, Inc
Obesity, Weight Change Trajectory
Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on Tirzepatide
Fractyl is evaluating Revita Duodenal Mucosal Resurfacing (DMR) in the REMAIN-1 pivotal study, which is designed to include two cohorts - an open label cohort referred to as REVEAL-1, and a randomized cohort, which includes both…
- Conditions
- Obesity, Weight Change Trajectory, Weight Change, Body
- Trial name
- REMAIN-1 (NCT06484114)
- Testing
- Revita Duodenal Mucosal Resurfacing (DMR)
- Where
- 32 sites in United States
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- Fractyl Health Inc.
GLP-1, Alcohol
Impact of GLP-1 Receptor Agonist Therapy on Alcohol Pharmacokinetics
This study is to learn how the weight loss drug tirzepatide (Zepbound) changes the way a body handles alcohol. 5 participants aged 21-55 who take Zepbound will be enrolled and can expect to be on study for up to 4 weeks.
- Trial name
- TAP (NCT07758231)
- Testing
- Acute Ethanol Dose
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Obesity, Menopause Hot Flashes
The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity
The purpose of this study is to determine the effect of tirzepatide on vasomotor symptoms and on measures of biological aging.
- Trial name
- NCT07218445
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Chronic Weight Management
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or Overweight
This randomized, double-blind, placebo-controlled single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ASC35 injection
- Trial name
- NCT07842640
- Testing
- ASC35 Injection B, for subcutaneous use, Tirzepatide
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Ascletis Pharma (China) Co., Limited
Dyspnea, Quality of Life
Gastric Sleeve-Induced Weight Loss on Shortness of Breath in Obesity
Most research to date on bariatric surgery outcomes has been about metabolic syndrome, a disorder very effectively treated by bariatric surgery.
- Trial name
- NCT05812183
- Testing
- Bariatric surgery, Medical weight loss
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Healthy
A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants
The purpose of this study is to look at how the body processes the commonly prescribed birth control pill, ethinylestradiol + norgestimate (EE/NGM), in healthy female participants and the effect of tirzepatide on how EE/NGM is…
- Trial name
- NCT04172987
- Testing
- Tirzepatide, EE/NGM
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Atrial Fibrillation, Obesity and Obesity-related Medical Conditions
Metabolic Surgery for Atrial Fibrillation Elimination
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It is estimated that between 3 and 6 million Americans are currently living with AF, while 12 million people in the United States will have AF in 2030.
- Trial name
- METSAFE (NCT07027969)
- Testing
- Roux-en-Y Gastric Bypass or Sleeve Gastrectomy, Anti-Obesity Medication (AOM) treatment
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Ali Aminian
Overweight and Obesity
A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending doses of WVE-007 when administered subcutaneously (SC) .
- Trial name
- INLIGHT (NCT06842186)
- Testing
- WVE-007
- Where
- 7 sites in United States, Moldova and 2 more
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Wave Life Sciences USA, Inc.
Healthy
Study of Tirzepatide in Healthy Participants
The purpose of this study is to look at how much tirzepatide gets into the bloodstream and how long the body takes to get rid of it. This study will involve a single dose of 14C radiolabelled tirzepatide.
- Trial name
- NCT04311424
- Testing
- 14C Tirzepatide
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease
Fibrosis Lessens After Metabolic Surgery
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia.
- Conditions
- Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis
- Trial name
- FLAMES (NCT06374875)
- Testing
- Metabolic surgery, Incretin-Based Therapy
- Where
- 22 sites in United States, Brazil and 11 more
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic